Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

Teleflex’s Rüsch EZ-Blocker Gets NMPA Approval for China Market

Fineline Cube Aug 8, 2025

US-based Teleflex Incorporated (NYSE: TFX) announced that its Rüsch EZ-Blocker single-use bronchial blocker has received...

Company Deals

Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million

Fineline Cube Aug 8, 2025

China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare...

Company Drug

Haisco’s HSK47388 Receives NMPA Clinical Trial Approval for Autoimmune Diseases

Fineline Cube Aug 8, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company

HutchMed Reports 9% Revenue Dip in H1 2025; FRUZAQLA Sales Grow Despite Overall Decline

Fineline Cube Aug 8, 2025

Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced its financial results for...

Company Deals

Westgene Partners with BGI Huo-Yan for mRNA Drug Development and Industrialization

Fineline Cube Aug 8, 2025

Chengdu Westgene Biopharma announced the establishment of a strategic partnership with Shenzhen BGI Huo-Yan Engineering...

Company Drug

Henlius’ HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma Treatment

Fineline Cube Aug 8, 2025

China’s Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration...

Company Medical Device

Cryofocus Medtech’s Cryoadhesion System Gains NMPA Approval for Commercialization

Fineline Cube Aug 8, 2025

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced that it has received approval from China’s...

Company

Zai Lab Announces Q2 2025 Results With 10% Revenue Growth Driven by Key Products

Fineline Cube Aug 8, 2025

China-based biotech Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced its financial results for the...

Company Drug

Sino Biopharmaceutical’s LM-24C5 Receives NMPA Approval for Phase 2 Clinical Trials in CEACAM5-Positive Solid Tumors

Fineline Cube Aug 8, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed LM-24C5 has received clinical trial...

Company Drug

Eli Lilly Reports Strong Q2 Growth but Shares Dip on Orforglipron Data

Fineline Cube Aug 8, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) reported another strong quarterly performance with...

Company

Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales

Fineline Cube Aug 7, 2025

US-based biopharma Amgen Inc. (NASDAQ: AMGN) released its Q2 2025 financial results, showing a 9%...

Others

Sunshine Lake Pharma Makes History With Dual-Entity Restructuring Listing on HKEX

Fineline Cube Aug 7, 2025

Guangdong China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main...

Company Drug Policy / Regulatory

NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender

Fineline Cube Aug 7, 2025

The National Healthcare Security Administration (NHSA) has released Q&As on the medical institutions’ volumes filing...

Company Drug

Neowise Biotechnology’s NW-101C Receives NMPA Clinical Trial Approval for PRAME-Targeted TCR-T Therapy

Fineline Cube Aug 7, 2025

China-based Neowise Biotechnology (Suzhou) Co., Ltd. announced that its self-developed PRAME-targeting autologous TCR-T cell therapy...

Company Drug

Dizal Pharma’s DZD8586 Granted FDA Fast Track Designation for CLL/SLL Treatment

Fineline Cube Aug 7, 2025

Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192) announced that its investigational product DZD8586 has been...

Company Drug

AstraZeneca’s Fasenra Approved for Pediatric Severe Eosinophilic Asthma in China

Fineline Cube Aug 7, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced the official approval of a new indication...

Company Drug

Sino Biopharmaceutical’s Rovadicitinib Granted Breakthrough Therapy Designation for Chronic Graft-versus-Host Disease

Fineline Cube Aug 7, 2025

China-based Sino Biopharmaceutical Limited (HKG: 1177) announced that its self-developed JAK/ROCK dual small molecule inhibitor,...

Company Deals

Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong

Fineline Cube Aug 7, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) officially launched its H-share global offering...

Company

BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales

Fineline Cube Aug 7, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business...

Company Medical Device

Sino Medical Sciences’ COMETIU Stent System and COMEX Catheter Receive FDA Breakthrough Designation

Fineline Cube Aug 7, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received breakthrough devices...

Posts pagination

1 … 169 170 171 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.